原力生命科学有限公司宣布任命罗锋博士为首席研发官

浏览量 1817

2020年7月29日，原力生命科学有限公司（IONOVA LIFE SCIENCE CO., LTD.，下简称为“原力”），一家扎根于粤港澳大湾区，以抗肿瘤药物研发为核心的创新型并已达到临床阶段的生物医药公司，近日宣布任命罗锋博士为公司首席研发官。罗博士为原力带来了在大型制药公司和生物技术公司研发新药的丰富经验，特别是在创新性癌症治疗药物的转化研究和临床研发领域。

在超过20年的药物研发过程中，罗博士领导、支持了数款新型肿瘤药物的NDA项目，其中最著名的是治疗肺癌的EGFR抑制剂艾维替尼（Abivertinib）、治疗尿路上皮癌的FGFR 抑制剂厄达替尼（Erdafitinib）和治疗白血病的BCR-ABL抑制剂达沙替尼（Dasatinib）。

罗博士还领导、参与了多种抗体药物的临床研发，这些药物包括EGFR西妥昔单抗、DR5单抗Tigatuzumab、VISTA单抗和PD-1/TIM3双抗。

此外，罗博士在商务开拓以及战略规划方面拥有丰富的经验。战略规划方面，他曾是中国强生肺癌中心的创始成员，为该中心的战略，特别是临床战略，做出了贡献。

原力董事长、美国国家工程院院士孙勇奎博士表示，“原力目前正处于扩展临床部，全力推进早期临床项目的阶段，我们很高兴罗博士在这个公司发展的令人振奋的时刻加入并领导临床研发部！罗博士将负责制定全球临床研发策略及领导在中国和美国/欧洲的运营。他的领导才能、丰富的经验以及在转化和临床研究方面的卓越成就对于推动原力在肿瘤学临床研发领域取得成功以及推动原力的长期发展与成功非常重要。”

有关原力的更多信息，请访问www.ionovabio.com。

Ionova Life Science Appoints Dr. Feng (Roger) Luo as Chief Development Officer

IONOVA LIFE SCIENCE CO., LTD., China, July 29, 2020 – IONOVA, a clinical-stage biotech company based at the Guangdong-Hong Long-Macao Greater Bay Area with pioneering innovative approaches to developing novel medicines to treat cancer and, today announced that Dr. Roger Luo has been appointed Chief Development Officer. Dr. Luo brings to IONOVA a wealth of experiences from big pharma and biotech companies in translational research and clinical development for innovative cancer treatment medicines.

In his more than 20 years of professional experiences in pharmaceutical R&D, Dr. Luo led and supported multiple NDA programs of novel oncology drugs, most notably EGFR inhibitor for lung cancer (Abivertinib), FGFR inhibitor for urothelial cancer (Erdafitinib), and BCR-ABL inhibitor for leukemia (Dasatinib). In addition, Dr. Luo led and participated the clinical development of multiple antibody drugs including anti-EGFR antibody (Cetuximab), anti-DR5 antibody (Tigatuzumab), anti-VISTA antibody, and anti-PD-1/Tim3 dual body. Furthermore, Dr. Luo has extensive experiences in business development as well as strategic planning. For the latter, he was a founding member of the Johnson & Johnson Lung Cancer Center in China and contributed to its strategy, particularly clinical strategy.

“We are elated bringing on board Dr. Luo to lead the global clinical development organization at such an exciting time in the company’s evolution as IONOVA advances its drug candidates into clinical space,” said Dr. Yongkui Sun, Chairman of the Board, and a member of the US National Academy of Engineering. ”Dr. Luo will be responsible for clinical development strategy and its execution in China and in the US/Europe. His leadership, extensive experiences as well as track record of accomplishments in translational and clinical research will be valuable in driving success in clinical development space for IONOVA’s oncology pipeline and in driving IONOVA’s long-term success.”

For more information on IONOVA, visit www.ionovabio.com.

– END –

推荐阅读

原力生命科学有限公司宣布完成1.26亿人民币A轮融资

是“吹哨人”，亦是排头兵——新冠疫苗赛场上的中国药企

生物制药行业融资规模有望创历史新高

2020年6月中国医疗健康投融资盘点：药物研发企业吸金超80亿，高瓴资本等7家机构出手频繁！

中国疫苗行业全景图